PDS Biotechnology Files 8-K
Ticker: PDSB · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Nov 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
TL;DR
PDS Biotech filed a routine 8-K, no major news.
AI Summary
PDS Biotechnology Corporation filed an 8-K on November 10, 2025, reporting other events and financial statements. The company, formerly known as Edge Therapeutics, Inc., is incorporated in Delaware and headquartered in Princeton, NJ. This filing does not appear to contain specific material events or financial details beyond the standard reporting requirements.
Why It Matters
This filing indicates PDS Biotechnology Corporation is meeting its regulatory reporting obligations with the SEC. It does not appear to disclose new material information at this time.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report and does not contain information that suggests an immediate change in risk for the company.
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- Edge Therapeutics, Inc. (company) — Former company name
- November 10, 2025 (date) — Date of report
- Princeton, NJ (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for PDS Biotechnology Corporation?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of November 10, 2025.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 10, 2025.
What is the principal executive office address for PDS Biotechnology Corporation?
The principal executive office address is 303A College Road East, Princeton, NJ 08540.
What was PDS Biotechnology Corporation's former company name?
PDS Biotechnology Corporation's former company name was Edge Therapeutics, Inc.
In which state is PDS Biotechnology Corporation incorporated?
PDS Biotechnology Corporation is incorporated in Delaware.
Filing Stats: 467 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2025-11-10 08:35:55
Key Financial Figures
- $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20058659_8k.htm (8-K) — 27KB
- ef20058659_ex99-1.htm (EX-99.1) — 33KB
- 0001140361-25-041286.txt ( ) — 193KB
- pdsb-20251110.xsd (EX-101.SCH) — 4KB
- pdsb-20251110_lab.xml (EX-101.LAB) — 21KB
- pdsb-20251110_pre.xml (EX-101.PRE) — 16KB
- ef20058659_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On November 10, 2025, PDS Biotechnology Corporation issued a press release announcing positive clinical and translational data presented at the 2025 Society for Immunotherapy of Cancer Annual Meeting. The presentations highlight immune-driven mechanisms and biomarkers that explain strong clinical activity of the Company's investigational HPV16-targeted immunotherapy PDS0101 and its novel, investigational immunocytokine PDS01ADC. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated November 10, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: November 10, 2025 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer